Vedall Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 14 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
About Vedall Pharma
Vedall Pharma Private Limited (VPPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 July 2010 and has a history of 14 years and six months. Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Sajid Mohammed, Mohammed Nayeem, and Aliya Peeran serve as directors at the Company.
Company Details
-
Location
Chennai, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24234TN2010PTC076476
-
Company No.
076476
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
06 Jul 2010
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
What products or services does Vedall Pharma Private Limited offer?
Vedall Pharma Private Limited offers a wide range of products and services, including Bird Food, Poultry & Animal Food, Animal Feed Supplement, Feed Additives, Cosmetics, Hair & Beauty Products, Cosmetic Chemical, Pet Furniture & Products, Pet Grooming Tools, Animal Medicines & Health Care, Veterinary Medicines, Nutraceuticals & Dietary Supplements.
Who are the key members and board of directors at Vedall Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sajid Mohammed
|
Whole-Time Director | 06-Jul-2010 | Current |
|
Mohammed Nayeem
|
Director | 06-Jul-2010 | Current |
|
Aliya Peeran
|
Whole-Time Director | 12-Dec-2015 | Current |
Financial Performance of Vedall Pharma.
Vedall Pharma Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vedall Pharma?
In 2017, Vedall Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Vedall Pharma?
Unlock and access historical data on people associated with Vedall Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vedall Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vedall Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
